Jacek Jassem - Researcher Profile | RDL Research Database

Publications

2 shown

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo , Richard S. Finn , Shukui Qin +19 more

2018 The Lancet 5118 citations

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst , Giuseppe Giaccone , Filippo de Marinis +19 more

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of his...

2020 New England Journal of Medicine 1580 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 6,698
Institution: Gdańsk Medical University

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-8875-6747

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.